Taking GLP-1 medications like Ozempic is linked to a smaller risk of developing epilepsy than taking DPP-4 inhibitors. | Drug ...

A new analysis suggests GLP 1 receptor agonists, the diabetes drugs that include semaglutide, dulaglutide and liraglutide, ...

Cassava Sciences shares fell after the company said the Food and Drug Administration had put a hold on its epilepsy drug trial. The stock fell 15% to $2.41 in after-hours trading Thursday. Through the ...

A large US-based study has found that people with type 2 diabetes taking GLP-1 drugs such as Ozempic may be slightly less ...

Individuals with epilepsy and their caregivers want improved communication and a broader base of information from their ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) ...

Glucagon-like peptide-1 receptor agonist therapy is associated with a reduced risk for epilepsy in adults with type 2 diabetes mellitus.

During this symposium, leading international epileptologists discussed the key challenges and opportunities that currently ...

Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

The study was carried out by an international group of researchers including epilepsy experts from the Epilepsy Society’s Chalfont Centre. It is believed to be the longest single-centre follow-up of ...

With an estimated more than 10 million cases, India accounts for nearly 20% of the global epilepsy burden. The number of ...